Big-pharma consolidation, biotech premiums, the inversion era, and the device roll-ups.
30 deals
What is on this page. Public transaction history — announced values, deal structures, defensive tactics and outcomes, each with its source and year. Everything here is drawn from the public record. El Dorado Capital's own segment analysis, buyer universes and live deal work are maintained privately and are not published.
Healthcare, Pharma & Life Sciences
Pfizer – Warner-Lambert (2000)
Value: $90 billion, all-stock. Announced November 1999, closed June 2000.
Structure: Stock-for-stock; began hostile. Warner-Lambert had a signed friendly merger with American Home Products; Pfizer, which co-promoted Warner-Lambert's Lipitor and had a matching right, launched a topping hostile bid and won after months of contest. American Home Products received a large breakup fee when its agreement was abandoned.
The thesis: Full ownership of Lipitor, the cholesterol drug Pfizer already co-marketed but did not own, plus Warner-Lambert's consumer and animal-health lines.
What actually happened: Deal closed; Pfizer became the world's largest pharmaceutical company. Lipitor went on to become the best-selling drug in pharmaceutical history before its patent expired in 2011.
Why it's in the encyclopedia: The template case of a matching-rights co-promotion partner using a hostile bid to break up a rival's signed friendly merger — and of a single blockbuster drug justifying an entire mega-merger.
Pfizer – Pharmacia (2003)
Value: approximately $60 billion, all-stock. Announced July 2002, closed April 2003.
Structure: Stock-for-stock exchange of Pharmacia shares for newly issued Pfizer shares; friendly. The Federal Trade Commission required both companies to divest a number of overlapping products, including an animal-health line and several generic-drug assets, before clearing the merger.
The thesis: Full economics of Celebrex and Bextra, the COX-2 painkillers Pfizer already co-promoted with Pharmacia under a prior alliance, plus Pharmacia's broader research pipeline and consumer-health portfolio (formed itself from Pharmacia's earlier 2000 merger with Monsanto's pharmaceutical arm).
What actually happened: Closed; Pfizer again became the world's largest pharmaceutical company by revenue. Bextra was withdrawn from the market in 2005 over cardiovascular and skin-reaction safety concerns, and Celebrex faced years of COX-2-class safety litigation and label restrictions that Pfizer inherited along with the drug.
Why it's in the encyclopedia: The second of Pfizer's back-to-back "acquire the co-promotion partner to capture 100% of a blockbuster" mergers in three years — and a reminder that a drug's inherited safety liability, not just its inherited revenue, travels with an acquisition.
Pfizer – Wyeth (2009)
Value: $68 billion, cash-and-stock. Announced January 2009, closed October 2009.
Structure: Roughly half cash, half stock; friendly. Financed partly through a novel bridge arrangement with several large banks that took equity-linked convertible preferred stock in Pfizer rather than pure debt — an unusual structure adopted because ordinary syndicated debt markets were largely frozen during the depths of the financial crisis.
The thesis: Diversify beyond small-molecule drugs into vaccines (Prevnar), biologics, animal health (Fort Dodge) and consumer health products ahead of Lipitor's looming 2011 U.S. patent expiration, which threatened to remove Pfizer's single largest revenue source almost overnight.
What actually happened: Closed; roughly 19,800 jobs were cut and multiple R&D sites closed in the ensuing integration, among the largest workforce reductions tied to any pharma merger. Wyeth's vaccine and biologics franchises became durable pillars of Pfizer's revenue for the following decade, largely offsetting the Lipitor decline as intended.
Why it's in the encyclopedia: One of the largest deals struck globally in the depths of the 2008-09 credit crisis, and an example of how an acquirer can structure creative, equity-linked financing to fund a mega-merger when normal syndicated debt markets are effectively shut — announced within weeks of Merck's own similarly sized Schering-Plough deal, illustrating that even a frozen credit market did not stop mega-merger activity in this sector.
Merck – Schering-Plough (2009)
Value: $41.1 billion, cash-and-stock. Announced March 2009, closed November 2009.
Structure: A "reverse merger": Schering-Plough was structured as the surviving legal entity (renamed Merck & Co.) even though Merck was the economic acquirer, because Schering-Plough was a party to a Remicade co-promotion agreement with Johnson & Johnson that would have terminated on a change of control if Merck had been the nominal acquirer.
The thesis: Merck wanted Schering-Plough's biologics pipeline, animal-health unit and scale ahead of its own patent expirations (Singulair, Cozaar).
What actually happened: Closed; the reverse-merger structure preserved the J&J Remicade arrangement, though the two companies later fought J&J in arbitration over the deal's effect on international marketing rights.
Why it's in the encyclopedia: The reference case for using "who is the legal survivor" as a drafting tool to avoid tripping a counterparty's change-of-control clause in a major contract.
Bristol-Myers Squibb – Celgene (2019)
Value: $74 billion, cash-and-stock, plus a Contingent Value Right (CVR) worth up to $9 per share (about $6.4 billion in aggregate) tied to FDA approval of three pipeline drugs by specified dates. Announced January 2019, closed November 2019.
Structure: Cash + stock + milestone-based CVR; friendly; one of the largest pharma mergers ever announced.
The thesis: Celgene's Revlimid blood-cancer franchise plus a pipeline including ozanimod and two cell therapies (later Breyanzi and Abecma).
What actually happened: Two of the three CVR milestones were missed on the contractual deadlines — Breyanzi's approval slipped past its date, in part due to COVID-19-related FDA delays — and the CVRs expired worthless in 2021, triggering extensive shareholder litigation against BMS that continued for years.
Why it's in the encyclopedia: The leading cautionary precedent on CVR design: a milestone tied to a hard regulatory-approval date is fragile against ordinary FDA review variance, let alone a pandemic, and litigation risk from a failed CVR can outlast the deal itself.
AbbVie – Pharmacyclics (2015)
Value: $21 billion, cash-and-stock. Announced March 2015, closed May 2015.
Structure: Cash + stock; a competitive process in which Johnson & Johnson — Pharmacyclics' existing commercialization partner on the drug in question, with contractual rights that complicated any outside acquirer's path — was also reported to have bid before AbbVie prevailed.
The thesis: Full economics of Imbruvica (ibrutinib), a breakthrough BTK-inhibitor blood-cancer drug for chronic lymphocytic leukemia and related blood cancers that AbbVie did not yet own any share of but that Pharmacyclics co-marketed and split profits on with J&J's Janssen unit under a pre-existing collaboration.
What actually happened: Closed; Imbruvica became a multibillion-dollar annual franchise, shared between AbbVie and J&J under the surviving collaboration terms, for several years before newer-generation BTK-inhibitor competitors and generic/biosimilar-adjacent pricing pressure eroded its growth trajectory in the 2020s.
Why it's in the encyclopedia: A clean example of a buyer paying a large premium to acquire the company behind a drug it already shared economics in via partnership, rather than the drug's full rights outright — and of a strategic partner (J&J) as a natural competing bidder with unusual insider knowledge of the asset's value.
Actavis – Allergan (2015)
Value: $70.5 billion, cash-and-stock. Announced November 2014, closed March 2015; the combined company took the Allergan name.
Structure: Cash + stock; friendly. Came directly after Allergan (the Botox maker) had spent much of 2014 fighting off a hostile approach backed by activist investor Bill Ackman's Pershing Square and Valeant Pharmaceuticals, ultimately finding Actavis as a white-knight buyer.
The thesis: Actavis — itself an Ireland-domiciled serial acquirer built through prior tax-driven mergers — wanted Allergan's branded aesthetics (Botox) and eye-care franchises, and adopted the more valuable Allergan brand name for the combined company.
What actually happened: Closed; the renamed Allergan became the target of Pfizer's failed $160 billion bid within a year, and was ultimately sold again, to AbbVie, in 2020 for $63 billion.
Why it's in the encyclopedia: Illustrates a white-knight defense against an activist-backed hostile bid, and one of the most-acquired large targets in modern pharma history — the same company changed hands twice more within six years.
Pfizer – Allergan (terminated, 2015–2016)
Value: approximately $160 billion, all-stock as proposed. Announced November 2015, terminated April 2016.
Structure: Stock-for-stock structured as a tax inversion — Pfizer would have redomiciled in Ireland via the nominally smaller Allergan. Pfizer paid Allergan a $400 million break/expense-reimbursement fee on termination.
The thesis: Combine to achieve scale and, centrally, cut Pfizer's effective corporate tax rate by moving its tax domicile to Ireland — Pfizer's second attempt at an inversion after AstraZeneca rebuffed it in 2014.
What actually happened: Killed within days by new U.S. Treasury anti-inversion regulations aimed at "serial inverters" and earnings-stripping; had it closed, it would have been the largest pharmaceutical merger and one of the largest corporate mergers ever announced.
Why it's in the encyclopedia: The deal that ended the 2010s corporate-inversion wave — a direct case study in a change of tax regulation unwinding a fully signed mega-merger.
AbbVie – Allergan (2020)
Value: $63 billion, cash-and-stock as announced. Announced June 2019, closed May 2020.
Structure: Cash + stock; friendly; cleared FTC review after both companies agreed to divest a small number of overlapping products, including AbbVie's brazikumab and Allergan's IL-23 pipeline asset. AbbVie subsequently ring-fenced Allergan's Botox/aesthetics business (Allergan Aesthetics) as a distinct reporting segment.
The thesis: Diversify AbbVie's revenue beyond Humira, which faced a 2023 U.S. biosimilar patent cliff, into aesthetics, eye care, gastroenterology and neuroscience — reducing single-product concentration that had made AbbVie dependent on one drug for the majority of its sales.
What actually happened: Closed amid the onset of COVID-19 market disruption, at a lower effective value than announced given AbbVie's stock decline between signing and close. Allergan Aesthetics performed well as a growth engine in the following years, helping offset Humira's subsequent steep U.S. revenue decline once biosimilar competitors launched in 2023.
Why it's in the encyclopedia: The clearest modern example of a "patent-cliff insurance" acquisition — a company facing a known, dated loss of exclusivity on its largest product buying diversified revenue streams years ahead of the cliff actually hitting.
Roche – Genentech (2009)
Value: Initial hostile tender offer valued at about $43.7 billion in July 2008 was rejected by Genentech's board as inadequate; final negotiated price, commonly reported near $46.8–47 billion, for the roughly 44% of Genentech Roche did not already own, agreed and closed March 2009. Sources differ on the exact per-share figures at each stage.
Structure: Cash tender offer; began hostile, turned friendly after Roche raised its price following negotiation with Genentech's special committee.
The thesis: Roche, Genentech's majority owner since a 1990 investment, wanted full ownership of Genentech's biologics engine (Avastin, Herceptin, Rituxan) and complete profit capture.
What actually happened: Closed; as a negotiated condition, Genentech's South San Francisco research operation retained unusual operating autonomy inside Roche, intended to protect its distinct R&D culture.
Why it's in the encyclopedia: The reference precedent for squeezing out the minority float of a majority-owned subsidiary via a hostile-to-friendly price escalation, plus a rare, explicit post-merger commitment to preserve an acquired unit's independent research culture.
Novartis – Alcon (2008–2011; spun off 2019)
Value: Acquired from Nestlé and public shareholders in stages: an approximately 25% stake in 2008, an additional roughly 52% stake exercised in 2010, and the remaining roughly 23% public float merged in for $12.9 billion cash-and-stock in 2011. Total consideration across all three steps is commonly reported in the $50–52 billion range; sources vary on the precise aggregate. Spun off again as an independent public company, Alcon Inc., in April 2019.
Structure: Staged controlling-stake purchases from a single seller (Nestlé) followed by a squeeze-out merger of remaining minority holders; later, a tax-free spinoff.
The thesis: Build an eye-care and ophthalmic-device leader alongside Novartis's pharma business (2008–11); a decade later, separate devices from pharma because the two businesses had diverging capital needs and investor bases (2019).
What actually happened: Alcon underperformed for periods inside Novartis, contributing to the 2019 decision to spin it off; independent Alcon has since traded as a standalone medtech company.
Why it's in the encyclopedia: A complete life-cycle case — buy a platform in stages over several years, then divest it whole a decade later — and a template for structuring a controlling-stake acquisition as multiple steps rather than one tender.
Astra – Zeneca (1999)
Value: Reported near $34–37 billion at announcement; sources vary on the exact figure for this all-stock merger of equals. Announced December 1998, closed April 1999.
Structure: Merger of equals, all-stock, cross-border between Sweden's Astra AB and the UK's Zeneca Group (itself ICI's 1993 pharmaceutical spinoff), forming the new UK-listed AstraZeneca plc with shareholders of both legacy companies exchanging their shares for stock in the combined entity roughly proportionate to each company's relative size.
The thesis: Combine Astra's Losec/Prilosec gastrointestinal franchise, then one of the world's best-selling drugs, with Zeneca's oncology, cardiovascular and agrochemical-adjacent pipeline, achieving the scale needed to compete against the wave of American pharma mega-mergers already under way in the late 1990s.
What actually happened: Closed; AstraZeneca became a top-five global pharmaceutical company and, fifteen years later, was itself the target of Pfizer's failed 2014 approach, a bid AstraZeneca's board successfully rejected.
Why it's in the encyclopedia: An early, comparatively balanced cross-border "merger of equals" in an industry that mostly trended toward one-sided premium takeovers — and the origin of a company that later became a landmark takeover target in its own right.
Ciba-Geigy – Sandoz (1996, forming Novartis)
Value: Reported near $30 billion in combined market value at announcement; sources vary on the precise figure for this all-stock combination. Announced March 1996, closed December 1996.
Structure: Merger of equals, all-stock, between two Basel-based Swiss conglomerates. As part of the strategic logic, the merged group's agrochemical and other non-core chemical businesses were later carved out and combined with a rival's equivalent unit to form Syngenta in 2000.
The thesis: Combine two diversified chemical-and-pharma conglomerates into a focused life-sciences leader, shedding non-core chemicals over time.
What actually happened: Closed as the largest industrial merger in history at the time; created Novartis, which became a serial acquirer in its own right (Alcon, Chiron, AveXis and others in the following decades).
Why it's in the encyclopedia: The foundational template for "merge first, then carve out the businesses that don't fit" — rather than trying to run every legacy division inside the combined company indefinitely.
Gilead Sciences – Pharmasset (2011)
Value: $11 billion, all cash, $137 per share (roughly an 89% premium to Pharmasset's prior close). Announced and closed November 2011.
Structure: All-cash acquisition; friendly.
The thesis: Acquire Pharmasset's pipeline — principally sofosbuvir, an oral hepatitis-C drug candidate with no approved product and limited clinical data at signing.
What actually happened: Sofosbuvir became Sovaldi and then Harvoni, curing hepatitis C for most patients and generating tens of billions of dollars in revenue within a few years — one of the highest-returning acquisitions in pharmaceutical history. Its roughly $1,000-per-pill U.S. list price triggered a 2014 U.S. Senate Finance Committee investigation and lasting payer and reputational backlash.
Why it's in the encyclopedia: The textbook case of a large premium paid for a single unapproved pipeline asset paying off spectacularly — cited as often for the pricing controversy that followed as for the financial return.
Gilead Sciences – Immunomedics (2020)
Value: $21 billion, all cash, $88 per share (roughly a 108% premium). Announced September 2020, closed October 2020.
Structure: All-cash tender offer; friendly and fast-closing, coming just weeks after AstraZeneca's separate acquisition of a stake in Daiichi Sankyo's antibody-drug-conjugate program, part of a broader industry scramble for the technology.
The thesis: Acquire Trodelvy (sacituzumab govitecan), a newly approved antibody-drug conjugate for metastatic triple-negative breast cancer, to build an oncology franchise beyond Gilead's core HIV and hepatitis-C businesses, which by 2020 had matured into large but slower-growing revenue bases.
What actually happened: Closed; Trodelvy's commercial launch and label expansion into additional breast-cancer subtypes progressed more slowly than the acquisition price implied analysts had expected, and the deal was widely characterized in industry commentary as underwhelming relative to its cost in the years after close.
Why it's in the encyclopedia: A marker of the antibody-drug-conjugate acquisition wave of the early 2020s, and a caution about paying peak-premium multiples for a single recently approved drug before its real-world commercial uptake is established.
Amgen – Horizon Therapeutics (2023)
Value: $27.8 billion, all cash, $116.50 per share. Announced May 2023, closed October 2023.
Structure: All-cash; the U.S. Federal Trade Commission sued in May 2023 to block the deal on a "cross-market bundling" theory — that Amgen could use rebates on unrelated blockbuster drugs to entrench Horizon's rare-disease drugs against future competitors — rather than a traditional direct-overlap theory. The FTC settled via a behavioral consent order barring bundled rebating practices in September 2023, clearing the closing.
The thesis: Acquire Tepezza (thyroid eye disease) and Krystexxa (chronic refractory gout), rare-disease drugs with limited competition and strong pricing power.
What actually happened: Closed after the FTC settlement; widely viewed as a partial defeat for the FTC's more aggressive merger-enforcement posture of that period.
Why it's in the encyclopedia: The leading modern precedent for "portfolio effects" antitrust theory in pharma — later large-portfolio pharma acquirers reference this consent order as the template outcome for cross-market rebating challenges.
AstraZeneca – Alexion Pharmaceuticals (2021)
Value: $39 billion, cash-and-stock. Announced December 2020, closed July 2021.
Structure: Cash + stock; friendly; AstraZeneca's largest deal to that point, financed with a mix of new debt and equity issuance.
The thesis: Build a rare-disease and complement-inhibitor franchise around Alexion's Soliris and Ultomiris, treatments for rare blood disorders including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, diversifying AstraZeneca beyond its core oncology, cardiovascular and respiratory categories into a higher-margin orphan-drug business.
What actually happened: Closed; Soliris itself faced a looming biosimilar and patent-related competitive threat in its core markets, which AstraZeneca argued the already-launched successor molecule Ultomiris — a longer-acting, less frequently dosed version of the same mechanism — would offset as patients and prescribers switched over.
Why it's in the encyclopedia: A clear example of orphan-drug M&A used defensively — acquiring a franchise mid-transition from an aging blockbuster to its own patent-protected successor, rather than waiting for the cliff to hit and then shopping for a replacement.
Johnson & Johnson – Momenta Pharmaceuticals (2020)
Value: $6.5 billion, all cash, $52.50 per share. Announced August 2020, closed October 2020.
Structure: All-cash tender offer; friendly and fast-moving, announced and closed within roughly two months.
The thesis: J&J's Janssen unit wanted nipocalimab, then a Phase 2 anti-FcRn antibody, to build an autoimmune-disease pipeline spanning myasthenia gravis, warm autoimmune hemolytic anemia and other antibody-mediated conditions, alongside Momenta's generic-biologics and biosimilars development expertise, which J&J valued separately.
What actually happened: Closed; nipocalimab progressed through pivotal trials over the following years and later reached FDA approval, validating the underlying pipeline bet, though on a multi-year timeline well past the typical near-term revenue payback horizon that characterizes deals for already-approved drugs.
Why it's in the encyclopedia: A useful counter-example to Pharmasset and Immunomedics: buying a mid-stage, single-mechanism pipeline platform for its scientific validation is a lower-immediate-risk but much longer-horizon bet than buying an approved or near-approved drug outright.
Medtronic – Covidien (2015)
Value: $42.9 billion is the figure most consistently reported; some contemporaneous reporting on total consideration including assumed debt cites a higher figure near $49.9 billion. Announced June 2014, closed January 2015.
Structure: Cash + stock structured as a tax inversion — Medtronic, then based in Minnesota, reincorporated in Ireland through the transaction, part-financing the cash consideration offshore to avoid U.S. repatriation tax. One of the highest-profile corporate inversions ever executed.
The thesis: Combine Medtronic's cardiac and neurological device lines with Covidien's surgical, vascular and respiratory portfolio at scale, while lowering Medtronic's effective corporate tax rate.
What actually happened: Closed; drew years of shareholder litigation over the inversion's tax treatment, since legacy Medtronic shareholders owed U.S. capital-gains tax on the deemed sale of their shares in the restructuring, distinct from the corporate-level tax benefit Medtronic itself received.
Why it's in the encyclopedia: The largest medtech tax inversion, and a clear illustration that an inversion's tax benefit to the corporation and its tax cost to the corporation's own existing shareholders are two separate, and separately litigated, questions.
Becton, Dickinson and Company – C.R. Bard (2017)
Value: $24 billion, cash-and-stock. Announced April 2017, closed December 2017.
Structure: Cash + stock; friendly; among the largest medical-device combinations of the decade, further consolidating a sector already reshaped by Medtronic-Covidien and Zimmer-Biomet.
The thesis: Broaden BD beyond its core injection systems, diagnostics and biosciences businesses into Bard's vascular access, urology, oncology and surgical-specialty device lines, creating a company with a much wider hospital product footprint.
What actually happened: Closed; BD subsequently absorbed significant, largely pre-existing product-liability exposure tied to legacy Bard products, including transvaginal and hernia mesh and inferior vena cava (IVC) filter litigation involving thousands of claimants, which weighed on BD's legal costs, reserves and reputation for years after close.
Why it's in the encyclopedia: A due-diligence lesson for medtech roll-ups: acquired product-liability litigation, even from products sold years before the deal was signed, becomes the acquirer's balance-sheet and reputational problem for a decade or more after close.
Abbott Laboratories – St. Jude Medical (2017)
Value: $25 billion, cash-and-stock. Announced April 2016, closed January 2017.
Structure: Cash + stock, partly debt-financed; friendly; closed after the FTC required divestitures of overlapping cardiac-device product lines to preserve competition. Abbott had also been pursuing a separate, unrelated acquisition of diagnostics company Alere at the same time, raising questions about how it would finance and integrate two large deals simultaneously.
The thesis: Make Abbott a top-tier cardiovascular device competitor to Medtronic and Boston Scientific across heart failure, electrophysiology, structural heart and vascular devices, adding scale it lacked after years of being a smaller player in cardiac rhythm management.
What actually happened: Closed; shortly afterward, the FDA issued a cybersecurity advisory and mandated a firmware update covering vulnerabilities in St. Jude's implanted cardiac devices and their Merlin@home remote-monitoring transmitters that researchers had shown could in theory allow unauthorized access — one of the first widely publicized medical-device cybersecurity incidents to surface right after a major acquisition closed.
Why it's in the encyclopedia: An early, concrete instance of connected-device cybersecurity risk crystallizing immediately post-close, foreshadowing device cybersecurity as now-standard medtech M&A due diligence rather than an afterthought.
Stryker – Wright Medical Group (2020)
Value: approximately $4 billion, all cash. Announced November 2019, closed November 2020.
Structure: All-cash tender offer; friendly; closing was delayed roughly a year by extended antitrust review and by pandemic-related market disruption in the interim.
The thesis: Consolidate the extremities (foot and ankle, upper extremities) and biologics segment of orthopedics, where Wright Medical, itself the product of a prior 2015 merger between Wright Medical Group and Tornier, was a focused specialist competing against larger generalist orthopedic players.
What actually happened: Closed after the FTC required divestitures of overlapping upper-extremities product lines to a third party to preserve competition; the roughly year-long gap between signing and close was unusually long for a deal of this size, driven by both the antitrust review and COVID-19 disruption to the closing timetable.
Why it's in the encyclopedia: Shows that even a narrowly focused, category-specific medtech bolt-on can draw a full antitrust review and multi-quarter closing delay when acquirer and target compete directly within the same orthopedic sub-specialty.
Boston Scientific / Johnson & Johnson – Guidant (2006)
Value: Boston Scientific ultimately paid $27 billion, cash-and-stock, to win Guidant after a bidding war; Johnson & Johnson had an earlier signed friendly agreement to acquire Guidant for roughly $25 billion (itself cut down from an original deal worth more, after Guidant's 2005 defibrillator recalls). Boston Scientific's winning bid was made in January 2006; the deal closed in April 2006.
Structure: Cash + stock; a public competitive bidding war; J&J ultimately declined to match Boston Scientific's final price given Guidant's recall-driven litigation and regulatory exposure.
The thesis: Both bidders wanted Guidant's cardiac-rhythm-management (pacemaker and defibrillator) business to compete at scale with Medtronic.
What actually happened: Boston Scientific won the auction but is widely regarded to have overpaid; it took substantial goodwill write-downs in subsequent years, faced federal investigations and extensive litigation tied to Guidant's undisclosed defibrillator defects, and spent years working down the debt taken on to fund the deal.
Why it's in the encyclopedia: The canonical medtech "winner's curse" — an auction won against a well-resourced strategic rival for a target carrying known but not fully priced product-liability risk, followed by years of write-downs and litigation.
Zimmer Holdings – Biomet (2015)
Value: $13.35 billion, cash-and-stock; total transaction value including assumed debt is cited by some reporting near $14 billion. Announced April 2014, closed June 2015; the combined company was renamed Zimmer Biomet Holdings.
Structure: Cash + stock; friendly. Biomet had been owned by a private-equity consortium (Blackstone, Goldman Sachs Capital Partners, KKR and TPG) since a 2007 leveraged buyout.
The thesis: Create the largest pure-play orthopedic device company by combining Zimmer's joint-reconstruction leadership with Biomet's dental, sports-medicine and extremities businesses.
What actually happened: Closed after an extended FTC review requiring divestitures; integration proved slower and costlier than modeled, and Zimmer Biomet subsequently faced manufacturing and quality-system issues that drew FDA scrutiny in the years after close.
Why it's in the encyclopedia: A large-scale private-equity-to-strategic exit via full merger rather than an IPO, and a case study in orthopedic-sector consolidation running into real post-merger execution risk.
UnitedHealth Group (Optum) – Change Healthcare (2022)
Value: $13 billion is the figure most consistently used in contemporaneous reporting for the combination with Optum; some accounts describe the consideration mix (cash, stock and assumed obligations) differently, so treat $13 billion as the headline figure rather than a precisely reconciled number. Announced January 2021, closed October 2022.
Structure: Cash-and-stock combination with UnitedHealth's Optum health-services arm. The U.S. Department of Justice sued in February 2022 to block the deal, arguing that folding a major claims-clearinghouse and data company into the country's largest health insurer would let UnitedHealth see, and potentially disadvantage, rival insurers' claims data.
The thesis: Combine Change Healthcare's claims-processing and data infrastructure with Optum's health-services and technology platform.
What actually happened: A federal judge rejected the DOJ's challenge in September 2022 — a rare government antitrust-suit loss — and UnitedHealth divested Change's ClaimsXten unit to resolve remaining concerns before closing. In February 2024, Change Healthcare suffered a large-scale ransomware attack that disrupted U.S. pharmacy and claims processing nationwide for weeks; UnitedHealth later disclosed direct and response costs exceeding $1 billion tied to the incident.
Why it's in the encyclopedia: A landmark modern vertical-merger antitrust loss for the government on a "data-access harms rivals" theory — now cited both for that failed legal theory and, after 2024, as the leading cautionary example of concentration risk in critical healthcare IT infrastructure.
Cigna – Express Scripts (2018)
Value: $67 billion, cash-and-stock. Announced March 2018, closed December 2018.
Structure: Cash + stock; friendly; announced within months of a separate large insurer-PBM combination in the same sector (not covered in this entry), as part of a broader wave of vertical integration between health insurers and pharmacy-benefit managers.
The thesis: Own a pharmacy-benefit manager outright to control drug-cost management for Cigna's health-plan members rather than contracting with an independent PBM.
What actually happened: Closed with limited conditions; the combined company became one of a small number of vertically integrated insurer-PBM groups that now dominate U.S. prescription-drug-benefit management and have drawn sustained congressional and FTC scrutiny over rebate practices in the years since.
Why it's in the encyclopedia: Completes the picture of the 2018 wave of payer-PBM vertical mergers that reshaped U.S. drug-pricing infrastructure — essential background for any later PBM antitrust or drug-pricing-reform discussion.
Amazon – One Medical (2023)
Value: $3.9 billion, all cash, $18 per share. Announced July 2022, closed February 2023.
Structure: All-cash; friendly; cleared FTC review without a formal enforcement action or a second request for information, despite public scrutiny of Amazon's expanding healthcare footprint and its prior PillPack pharmacy acquisition.
The thesis: Acquire a national, membership-based primary-care network (One Medical's brick-and-mortar clinics plus telehealth and employer-benefit relationships) to combine with Amazon's pharmacy business (PillPack, acquired 2018) and its own earlier internal telehealth effort, positioning Amazon as a genuine primary-care provider rather than just a logistics and pharmacy player.
What actually happened: Closed; Amazon subsequently wound down its separate, earlier Amazon Care telehealth service, consolidating its healthcare strategy around One Medical's clinic-and-membership model instead.
Why it's in the encyclopedia: The leading "big technology platform enters brick-and-mortar healthcare" precedent, and a data point on the limits of antitrust appetite for reaching into tech-platform healthcare expansion even during an otherwise aggressive merger-enforcement period.
Pfizer – AstraZeneca (failed bid, 2014)
Value: Pfizer's proposals escalated over several weeks from roughly $99 billion to a final offer commonly reported between $117 billion and $119 billion (reports vary by exchange rate and date), all-share-plus-cash as proposed. May 2014.
Structure: Proposed as a UK scheme of arrangement that would have redomiciled the combined company in the UK — another tax-inversion-driven mega-merger; never formalized into a binding agreement because AstraZeneca's board rejected every proposal as inadequate.
The thesis: Add AstraZeneca's oncology pipeline to Pfizer's portfolio while lowering Pfizer's effective tax rate through UK domicile.
What actually happened: Pfizer walked away in May 2014 after AstraZeneca's board refused further engagement and after facing political backlash in the UK over potential research-site closures and job losses; under UK takeover rules, Pfizer was then barred from a new approach for six months.
Why it's in the encyclopedia: A leading example of a target defeating a mega-bid through straightforward valuation rejection combined with political and public-interest pressure (jobs, national R&D base) — and a direct precursor to the U.S. Treasury rules that later killed the Pfizer-Allergan inversion.
Illumina – GRAIL (2021; unwound 2023–2024)
Value: approximately $8 billion, cash-and-stock, plus a contingent-value-right component tied to GRAIL's future performance. Announced September 2020, closed August 2021.
Structure: Cash + stock + CVR. Illumina — GRAIL's former parent, which had spun it out in 2016 — closed the deal before EU and FTC merger review had concluded, a deliberate "closing at risk" strategy betting it would prevail on appeal.
The thesis: Fold GRAIL's multi-cancer early-detection blood test back into Illumina to control the full sequencing-to-diagnostic pipeline.
What actually happened: Both the FTC and the European Commission ultimately ordered Illumina to divest GRAIL. The EU's order was itself later overturned on jurisdictional grounds by the EU's top court in 2024 — ruling Brussels had lacked authority to review the deal at all under the "killer acquisition" theory it had invoked — but by then Illumina had already committed to divest under the FTC's separate, still-standing order. Illumina spun GRAIL back off as an independent public company in 2024, and Illumina's CEO departed amid the fallout.
Why it's in the encyclopedia: The leading modern case on closing a deal "at risk" during active merger review, and on the limits of EU jurisdiction over acquisitions that fall below normal notification thresholds — cited on both sides of the antitrust-jurisdiction debate.
Value: Step one (2012): roughly $6.7 billion cash-and-stock for a 45% stake in Alliance Boots, with a call option for the balance. Step two (2014): roughly $15.3 billion cash-and-stock to exercise the option and acquire the remaining 55%. Total consideration across both steps is commonly cited in the $27–28 billion range, though sources differ on whether that includes assumed debt.
Structure: A staged, option-based acquisition — a minority stake purchased first with a call option exercised later — rather than a single transaction; the combined company was renamed Walgreens Boots Alliance in December 2014.
The thesis: Build the first global, pharmacy-led retail health and wellbeing enterprise, combining Walgreens' U.S. retail-pharmacy footprint with Alliance Boots' European retail and pharmaceutical-wholesale/distribution business, with Alliance Boots executive Stefano Pessina taking a leading strategic role.
What actually happened: Closed; despite market speculation at signing that the combined group might redomicile outside the U.S. for tax reasons, Walgreens Boots Alliance kept its U.S. incorporation after political and public pressure. Pessina became CEO and later executive chairman and the company's largest shareholder for over a decade; the company was ultimately taken private by Sycamore Partners in 2025.
Why it's in the encyclopedia: The reference example of a staged option-to-acquire structure as an alternative to a single upfront takeover, and of public and political pressure deterring a widely speculated tax-motivated inversion even after a deal had already been structured.